FDA approves Takeda's orexin drug for narcolepsy
One of the most closely watched commercial drug races is now off and running, after Takeda snagged FDA approval of its orexin agonist to treat narcolepsy type 1. The FDA
The Food and Drug Administration (FDA) recently approved a groundbreaking treatment for narcolepsy developed by Takeda pharmaceutical company. This new drug, Orzeyful, represents a novel treatment class that scientists hope could revolutionize the management of sleep disorders and potentially address various neurologic conditions.
The twice-daily pill, marketed as Orzeyful, is an orexin receptor agonist, designed to treat narcolepsy type 1, a debilitating condition characterized by an orexin neuron deficiency, causing daytime sleepiness and muscle weakness. Given its potential, the drug is anticipated to be highly desirable for patients who have previously experienced misuse risks and persistent sleepiness while using stimulants and sodium oxybates.
Two Phase 3 trials demonstrated that Orzeyful effectively increased daytime wakefulness, reduced daytime sleepiness, decreased muscle weakness frequency, and enhanced attentiveness among patients. For further details, refer to STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
